HPN536 Fixed IV 6 to 560 ng/kg + HPN536 1 Prime Step IV 600-1200 ng/kg Target + 2 Prime Step IV 900-14000 ng/kg Target
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancers Associated With Mesothelin Expression
Conditions
Advanced Cancers Associated With Mesothelin Expression
Trial Timeline
Apr 16, 2019 → Jan 4, 2023
NCT ID
NCT03872206About HPN536 Fixed IV 6 to 560 ng/kg + HPN536 1 Prime Step IV 600-1200 ng/kg Target + 2 Prime Step IV 900-14000 ng/kg Target
HPN536 Fixed IV 6 to 560 ng/kg + HPN536 1 Prime Step IV 600-1200 ng/kg Target + 2 Prime Step IV 900-14000 ng/kg Target is a phase 1 stage product being developed by Merck for Advanced Cancers Associated With Mesothelin Expression. The current trial status is completed. This product is registered under clinical trial identifier NCT03872206. Target conditions include Advanced Cancers Associated With Mesothelin Expression.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03872206 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Cancers Associated With Mesothelin Expression